Fibrocell Science (NASDAQ:FCSC) Q2 results:
Revenues: $21.8M.
Net income: $11.5M (+471%); EPS: $1.12 (+329%) due to collaboration deal with Castle Creek Pharmaceuticals.
Cash and equivalents: $13.7M.
Enrollment and dosing in Phase 3 study of FCX-007 in RDEB should be completed in Q3 2020. Data collection for the primary endpoint should wind up a quarter later. If all goes well, a U.S. marketing application will be filed in 2021.
Topline data from the first portion of a Phase 1/2 study of FCX-013 in scleroderma should be available in mid-2020.
Shares are up 11% premarket on modest volume.
Previously: Fibrocell Science EPS of $1.12 (Aug. 14)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.